Stopping rules for phase II studies

British Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2001, Pages 523-529

  Stallard, N ^a   Whitehead, J ^a   Todd, S ^a   Whitehead, A ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

Clinical trial design; Early stopping; Group sequential designs

Indexed keywords

CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EVALUATION; EXPERIMENT; HUMAN; INTERMETHOD COMPARISON; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BAYES THEOREM; BIAS (EPIDEMIOLOGY); CLINICAL TRIALS, PHASE II; DATA INTERPRETATION, STATISTICAL; DECISION THEORY; HUMANS; NEOPLASMS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 0034818670     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0306-5251.2001.01381.x     Document Type: Article

References (23)

1. Interim analyses in phase III studies
2. Practical Bayesian guidelines for phase IIB clinical trials
3. Statistical considerations for pilot studies
4. One-sample multiple testing procedure for phase II clinical trials
5. Optimal two-stage designs for phase II clinical trials
6. Optimal three-stage designs for phase II cancer clinical trials
7. Bivariate sequential designs for phase II trials
8. The determination of the number of patients required in a preliminary and a follow-up trial of a new chmotherapeutic agent
9. An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives
10. Ethics and decision theory in a clinical trial involving severe disfigurement
11. A sample-size-optimal Bayesian decision procedure for sequential pharmaceutical trials
12. Bayesian interim analysis of phase II cancer clinical trials
13. Sample size determination for phase II clinical trials based on Bayesian decision theory
14. Approximately optimal designs for phase II clinical studies
15. Decision theoretic designs for phase II clinical trials with multiple outcomes
16. Group-sequential clinical trials: A classical evaluation of Bayesian decision-theoretic designs
17. One-sided sequential stopping boundaries for clinical trials: A decision-theoretic approach
18. A two-stage design for choosing among several experimental treatments and a control in clinical trials
19. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation
20. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials
21. Designing phase II studies in the context of a programme of clinical research
22. Sample sizes for phase II and phase III clinical trials, an integrated approach